ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
- Conditions
- Hidradenitis Suppurativa (HS)
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 17
- Registration Number
- NCT03001115
- Locations
- 🇰🇷
Kyungpook National Univ Hosp /ID# 162930, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷Seoul National Univ Bundang ho /ID# 202254, Seongnam, Gyeonggido, Korea, Republic of
🇰🇷Ajou University Hospital /ID# 163243, Suwon-si, Gyeonggido, Korea, Republic of
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000075
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 443
- Registration Number
- NCT02993523
- Locations
- 🇺🇸
Emory Midtown Infectious Disease Clinic /ID# 162534, Atlanta, Georgia, United States
🇺🇸Northwestern University Feinberg School of Medicine /ID# 201133, Chicago, Illinois, United States
🇺🇸University of Chicago Medicine /ID# 154108, Chicago, Illinois, United States
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 163
- Registration Number
- NCT02988960
- Locations
- 🇨🇦
University Health Network_Princess Margaret Cancer Centre /ID# 200819, Toronto, Ontario, Canada
🇺🇸The Angeles Clinic and Researc /ID# 156324, Los Angeles, California, United States
🇺🇸The University of Chicago Medical Center /ID# 155264, Chicago, Illinois, United States
A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
- Conditions
- Ankylosing Spondylitis (AS)SpondylarthritisPsoriatic Arthritis
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 139
- Registration Number
- NCT02988674
- Locations
- 🇷🇺
Institution KhMAO-Ugra /ID# 154381, Khanty-mansiysk, Russian Federation
🇷🇺State Clinical Hospital /ID# 154373, Moscow, Russian Federation
🇷🇺Research Institute of Rheum /ID# 154378, Moscow, Russian Federation
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: risankizumab
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 145
- Registration Number
- NCT02986373
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 378
- Registration Number
- NCT02985879
- Locations
- 🇺🇸
Usc /Id# 149773, Los Angeles, California, United States
🇺🇸Mayo Clinic - Scottsdale /ID# 144893, Scottsdale, Arizona, United States
🇺🇸Ucsd /Id# 144905, La Jolla, California, United States
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 210
- Registration Number
- NCT02980731
- Locations
- 🇦🇺
St George Hospital /ID# 154212, Kogarah, New South Wales, Australia
🇦🇺Liverpool Hospital /ID# 154950, Liverpool, New South Wales, Australia
🇦🇺Gold coast University Hospital /ID# 150833, SouthPort, Queensland, Australia
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 50
- Registration Number
- NCT02968173
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT02966756
- Locations
- 🇦🇺
Monash Health - Monash Medical Centre /ID# 201263, Clayton, Victoria, Australia
🇨🇳Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 156576, Beijing, Beijing, China
🇦🇺Concord Repatriation General Hospital /ID# 201261, Concord, New South Wales, Australia